Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CStone Pharmaceuticals Co. Ltd.

http://www.cstonepharma.com

Latest From CStone Pharmaceuticals Co. Ltd.

H1 Winners And Laggards In China's Sizzling Home-Grown IO market

Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.

China ImmunoOncology

BeiGene Head of R&D Lai Wang On Going Global

The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.

Regulation Drug Approval Standards

BeiGene Head of R&D Lai Wang On Going Global

The Chinese company's R&D leader talked to Scrip about the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.

Business Strategies Clinical Trials

No OS Gain For 34 China-Approved Cancer Drug Indications

Sweeping regulatory reforms put China in catch-up mode for the approval of oncology drugs, some of which have been cleared for marketing only in the country. But how does the deluge of new products measure up in terms of actual overall survival benefits? A new study by Peking University scholars and specialists unveils some surprising results.

China Cancer
See All

Company Information

UsernamePublicRestriction

Register